NASDAQ:NXTC
NextCure Inc. Stock News
$1.72
+0.140 (+8.86%)
At Close: May 09, 2024
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
07:00am, Tuesday, 02'nd Apr 2024
BELTSVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich
06:00am, Saturday, 23'rd Mar 2024
The bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of th
Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing
11:16am, Monday, 25'th Dec 2023
NextCure, Inc. (NXTC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mea
NextCure (NXTC) Down on Shelving Plans to Develop Candidate
12:46pm, Friday, 15'th Dec 2023
NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.
NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
07:00am, Monday, 20'th Nov 2023
BELTSVILLE, Md., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy
01:32pm, Tuesday, 07'th Nov 2023
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
07:00am, Thursday, 31'st Aug 2023
BELTSVILLE, Md., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure to Present at the JMP Securities Life Sciences Conference
07:00am, Tuesday, 09'th May 2023
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicine
NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference
07:00am, Tuesday, 11'th Apr 2023
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure to Present at SVB Securities Global Biopharma Conference
07:00am, Tuesday, 07'th Feb 2023
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure to Present at Upcoming Investor Conferences
08:00am, Tuesday, 22'nd Nov 2022
BELTSVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin
NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting
09:15am, Thursday, 03'rd Nov 2022
BELTSVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade
01:32pm, Wednesday, 05'th Oct 2022
NextCure, Inc. (NXTC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NextCure to Present at the Ladenburg Thalmann Healthcare Conference
08:00am, Thursday, 22'nd Sep 2022
BELTSVILLE, Md., Sept. 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedici
NextCure to Present at the JMP Securities Life Sciences Conference
08:00am, Wednesday, 08'th Jun 2022
BELTSVILLE, Md., June 08, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicin